Patients with non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) with concurrent diabetes or obesity might benefit from the hepatic anti-inflammatory effects observed in clinical studies, though GLP-1 receptor agonists are not yet FDA-approved specifically for liver disease
william July 25, 2026 Return policy Shipping Policy 4.7 (32) 42% off (1) 36% off 22% off 27% off 4.4 (9.6K) 4.6 (455.1K) 4.9 (536.2K) 4.5 (180.2K) 4.3 (428.8K) 4.6 (118.1K) 4.5 (94.6K) 4.8 (177.8K) 4.8 (80.7K) 4.7 (175.5K)
(PDF 186 KB) Authors original submitted files for images Below are the links to the authors original submitted files for images
Ingredients Reduced Glutathione: L-Glutathione (reduced form) 500mg per capsule Tripeptide compound (L-glutamate, L-cysteine, glycine) Our reduced glutathione delivers the active tripeptide form that cells can directly utilize without requiring conversion processes
NAD+ benefits build up slowly and stay longer
Pre-Blend Weekly Schedule Example Pre-blend dose at each titration step Phase Start Weeks 1-4 Draw Volume 0.40 mL (40 units) Reta Delivered 2.0 mg Cag Delivered 0.4 mg Phase Step 1 Weeks 5-8 Draw Volume 0.60 mL (60 units) Reta Delivered 3.0 mg Cag Delivered 0.6 mg Phase Step 2 Weeks 9-16 Draw Volume 0.80 mL (80 units) Reta Delivered 4.0 mg Cag Delivered 0.8 mg Phase Step 3 Weeks 17-20 Draw Volume 1.20 mL (120 units) Reta Delivered 6.0 mg Cag Delivered 1.2 mg Phase Step 4 Weeks 21-24 Draw Volume 1.60 mL (160 units) Reta Delivered 8.0 mg Cag Delivered 1.6 mg Phase Maintenance Weeks 25+ Draw Volume 2.40 mL (240 units) Reta Delivered 12.0 mg Cag Delivered 2.4 mg One injection per week